title: [Health economics analysis of specific immunotherapy in allergic rhinitis accompanied with asthma].
abstract: OBJECTIVE
  To investigate the cost-effectiveness of standardized specific immunotherapy (SIT) for allergic rhinitis patients accompanied with asthma (ARAS) in China.
  
  
  METHODS
  Forty ARAS patients sensitized with house dust mite (HDM) were administered with SIT (SIT group) or merely medicine treatment (control group). Alutard dermatophagoides pteronyssinus vaccine from ALK company was used for immunotherapy. The usage of symptom control medicine was according to the ARIA and GINA guideline. Cost-effectiveness ratio (CER) and Incremental cost-effectiveness ratio(ICER) analysis was conducted. The effectiveness was measured in terms of symptom scores, quality of life, objective improvement of rhinitis and asthma. Sensitive analysis was conducted to verify the stability of the results.
  
  
  RESULTS
  The cost of SIT group for 1 year (6578 yuan) was higher than that of control group (1733.3 yuan), while the cost-effectiveness ratio and incremental cost-effectiveness ratio of SIT group were significant better than that of control group in all items. CER was 1686.7 yuan in SIT group compared with 3466.6 yuan in control group for nasal symptom scores, 4698.6 yuan in SIT group compared with 5777.8 yuan in control group for asthma symptom scores, 3462.1 yuan in SIT group compared with 8666.7 yuan in control group. The sensitive analysis of the price 10 percent higher or lower showed the same results.
  
  
  CONCLUSIONS
  The cost-effectiveness of specific immunotherapy (SIT) for mite sensitized ARAS patients was better than that of merely medicine treatment.
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. ylly80331@163.com
authors.forename: Jianjun
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
authors.forename: Jisheng
authors.initials: J
authors.lastname: Xiang
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
authors.forename: Qiumei
authors.initials: Q
authors.lastname: Shi
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
authors.forename: Huifang
authors.initials: H
authors.lastname: Tan
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.
authors.forename: Weijia
authors.initials: W
authors.lastname: Kong
mesh_terms: D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000191:economics* / Q000628:therapy; D002648:Child; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000191:economics*; D008297:Male; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000191:economics* / Q000628:therapy; D055815:Young Adult